BATM Advanced Communications Ltd (LON:BVC) has appointed medtech industry veteran Dr David Perry as chief executive officer of its subsidiary, Adaltis.
As part of the restructuring of the senior team, the board of Adaltis is promoting the current general manager, Marco Spadaciolli, to chief operating officer.
Dr Perry has more than 20 years' international experience in developing and bringing to global markets new medical devices, and pharmaceutical and biotechnological products across multiple therapy areas, and in small and large companies. Most recently he served as principal of Lilium Bioscience, a company dedicated to bringing to market novel therapeutic and medical-device products in the areas of biosurgery, orthopaedics, regenerative medicine and dermatology.
"We are delighted to have David join Adaltis. We believe that Adaltis is maturing to be an important player in the in-vitro diagnostic field and is making the necessary steps to achieve that. We look forward to leveraging David's experience as we take Adaltis to the next stage of its development,” said Dr Zvi Marom, chief executive officer of BATM.